• 1
    Grider JR, Foxx-Orenstein AE, Jin JG. 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998; 115(2): 37080.
  • 2
    Jin JG, Foxx-Orenstein AE, Grider JR. Propulsion in guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5-HT3 receptors. J Pharmacol Exp Ther 1999; 288(1): 937.
  • 3
    Burleigh DE & Borman RA. Short-circuit current responses to 5-hydroxytryptamine in human ileal mucosa are mediated by a 5-HT4 receptor. Eur J Pharmacol 1993; 241: 1258.
  • 4
    Kellum JM, Albuquerque FC, Stoner MC, Harris RP. Stroking human jejunal mucosa induces 5-HT release and Cl secretion via afferent neurons and 5-HT4 receptors. Am J Physiol 1999; 277(3 Part 1): G51520.
  • 5
    Schikowski A, Mathis C, Thewissen M. Dose-dependent modulation of rectal afferent sensitivity by a 5-HT4 receptor agonist. Gastroenterology 1999; 116: A643A643(Abstract).
  • 6
    Coelho AM, Rovira P, Fioramonti J, Bueno L. Antinociceptive properties of HTF 919 (tegaserod), a 5-HT4 receptor partial agonist, in a rat model of colorectal distension. Gastroenterology 2000; 118(4 Suppl. 2): A4393A4393(Abstract).
  • 7
    Buchheit KH, Gamse R, Giger R, et al. The serotonin 5-HT4 receptor. 1. Design of a new class of agonists and receptor map of the agonist recognition site. J Med Chem 1995; 38: 232630.
  • 8
    Pfannkuche HJ, Buhl T, Gamse R, et al. The properties of a new prokinetically active drug, SDZ HTF 919. Neurogastroenterol Motil 1995; 7: 280280.
  • 9
    Nguyen A, Camilleri M, Kost LJ, et al. SDZ HTF 919 stimulates canine colonic motility and transit in vivo. J Pharmacol Exp Ther 1997; 280(3): 12706.
  • 10
    Fioramonti J, Million M, Bueno L. Investigations on a 5-HT4 agonist (SDZ HTF 919) and its main metabolite in conscious dogs: effects on gastrointestinal motility and impaired gastric emptying. Gastroenterology 1998; 114: A752: G3103G3103.
  • 11
    Appel S, Kumle A, Hubert M, Meier R. Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor agonist, in a model of slow colonic transit. Clin Pharmacol Ther 1997; 62: 54655.
  • 12
    Degen LP, Matzinger D, Merz M, et al. Tegaserod (HTF 919) a 5-HT4 receptor partial agonist accelerates gastrointestinal (GI) tract. Neurogastroenterol Motil 2000; 12(4): 382382.
  • 13
    Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118: 4638.
  • 14
    Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001; 120: 35460.
  • 15
    Poen AC, Felt-Bersma RJ, Van Dongen PA, Meuwissen SG. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther 1999; 13: 14937.
  • 16
    Appel-Dingemanse S, Lemarechal MO, Kumle A, Hubert M, Legangneux E. Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration. Br J Clin Pharmacol 1999; 47: 48391.DOI: 10.1046/j.1365-2125.1999.00936.x
  • 17
    Gibaldi M & Perrier F. Pharmacokinetics, 2nd edn. revised and expanded. New York and Basel: Marcel Decker Inc., 1982.
  • 18
    Degen LP & Phillips SF. Variability of gastrointestinal transit in healthy women and men. Gut 1996; 39(2): 299305.
  • 19
    Vassallo MJ, Camilleri M, Sullivan SN, Thomforde GM. Effects of erythromycin on gut transit in pseudo-obstruction due to hereditary coproporphyria. J Clin Gastroenterol 1992; 14(3): 2559.
  • 20
    Stivland T, Camilleri M, Vassallo M, et al. Scintigraphic measurement of regional gut transit in idiopathic constipation. Gastroenterology 1991; 101: 10715.
  • 21
    Camilleri M, Colemont LJ, Phillips SF, et al. Human gastric emptying and colonic filling of solids characterized by a new method. Am J Physiol 1989; 257(2 Part 1): G28490.
  • 22
    Camilleri M, Zinsmeister AR, Greydanus MP, Brown ML, Proano M. Towards a less costly but accurate test of gastric emptying and small bowel transit. Dig Dis Sci 1991; 36(5): 60915.
  • 23
    Greydanus MP, Camilleri M, Colemont LJ, Phillips SF, Brown ML, Thomforde GM. Ileocolonic transfer of solid chyme in small intestinal neuropathies and myopathies. Gastroenterology 1990; 99(1): 15864.
  • 24
    McCallum RW, Prakash C, Campoli-Richards DM, Goa KL. Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs 1988; 36(6): 65281.
  • 25
    Wiseman LR & Faulds D. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994; 47: 11652.
  • 26
    Bran S, Murray WA, Hirsch IB, Palmer JP. Long QT syndrome during high-dose cisapride. Arch Intern Med 1995; 155: 7658.
  • 27
    Briejer MR, Schuurkes JA, Sarna SK. Idiopathic constipation: too few stools and too little knowledge. Trends Pharmacol Sci 1999; 20(1): 13.DOI: 10.1016/S0165-6147(98)01278-4